Please login to the form below

Not currently logged in
Email:
Password:

ALK Abello

This page shows the latest ALK Abello news and features for those working in and with pharma, biotech and healthcare.

Positive mid-stage trial gives Allergy’s investors some welcome relief

Positive mid-stage trial gives Allergy’s investors some welcome relief

There are already immunotherapies on the market for grass pollen allergy - including for example Alk Abello/Merck &Co’s oral Grazax/Grastek product - but these can take months of treatment to

Latest news

  • Merck gets US green light for allergy immunotherapy Merck gets US green light for allergy immunotherapy

    Merck was given the nod for the product in Canada earlier this year and it has been sold by Alk-Abello as Grazax in Europe since 2006. ... The FDA is also reviewing Merck and ALK-Abello's ragweed allergy Ragwitek, which was backed by the agency's

  • FDA backs a brace of allergy immunotherapies FDA backs a brace of allergy immunotherapies

    Turning to Grastek, which was originally developed by Danish drugmaker Alk-Abello, the panel recommended approval in people aged five to 65, once again on the proviso that those taking it

  • UK's MHRA reveals advertising lapses UK's MHRA reveals advertising lapses

    iMed Systems promotes allergy treatment. The first complaint upheld by the UK regulator covers a complaint made by Meda Pharmaceuticals and ALK Abello about iMed's promotion of its injectable pen

  • FDA to review Merck & Co's allergy immunotherapy FDA to review Merck & Co's allergy immunotherapy

    Both the ragweed and grass pollen immunotherapies are developed in partnership with Denmark-based firm ALK-Abello and Merck has rights to develop, market and distribute approved products in the US,

  • Three new members at ABPI Three new members at ABPI

    ALK- Abello, Shionogi and Randox join UK trade body. The trade body for the UK's pharma industry has added three new companies to its list of members. ... ALK- Abello is a specialist biopharma company, which is focused on the development of treatments

More from news
Approximately 3 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    And Finally, Reality Bites. ALK-Abello has issued a press release announcing that Merck &Co has walked away from the deal agreed in 2007 (with Schering-Plough) for the allergy treatments ... No sales figures have been released by either side, but

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • ALK-Abello appoints Søren Jelert as CFO ALK-Abello appoints Søren Jelert as CFO

    He will be based at the company’s headquarters in Denmark. Dansih allergy immunotherapy company ALK-Abello has appointed Søren Jelert as its new chief financial officer, a role that sees ... ALK.”. Jelert will be based at ALK’s headquarters in

  • Cello Health Consulting expands its UK team Cello Health Consulting expands its UK team

    Tarplee has over 30 years of life science industry experience and previously worked for the likes of Adherium, ALK Abello, Sanofi and Abbott.

  • ALK Abelló's John Tarplee joins Adherium ALK Abelló's John Tarplee joins Adherium

    UK. He brings over 30 years of sales and market expansion expertise, most recently in the role of senior vice president at Danish immunotherapy company ALK Abelló where he oversaw its

  • Lars Dreiøe joins Sobi in senior quality and compliance role Lars Dreiøe joins Sobi in senior quality and compliance role

    Moves to the Swedish rare diseases company from Denmark's ALK. Swedish rare diseases company Sobi has appointed Lars Dreiøe as senior vice president chief quality and compliance officer. ... He will join the firm in January from Danish allergy vaccine

  • ALK Abello appoints UK managing director ALK Abello appoints UK managing director

    Sean Connor joins from Shire. ALK Abello has appointed Sean Connor to the role of UK managing director and director of international markets.

More from appointments
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics